InVivoMAb Anti-Dog TNFa/TNF-alpha Antibody (Iv0271)

Description: InVivoMAb Anti-Dog TNFa/TNF-alpha Antibody (Iv0271) [Iv0271] (RA14527) is a dog monoclonal antibody detecting TNF in Blocking, ELISA, FCM. Suitable for Dog.
Highlights:
• Multi-Application — Validated across multiple applications.
• Flow Cytometry — Validated for flow cytometry applications.
Host species: Dog
Isotype: IgG1, kappa
Species reactivity: Dog
Form: Liquid
Storage buffer: 0.01M PBS, pH 7.4.
Concentration: 1 mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Blocking, ELISA, FCM
Target: TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: Please contact with the lab for this information.
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: Tumor necrosis factor (TNFa/TNF-alpha) is a ~25 kDa protein. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance. TNFa is the therapeutic target of adalimumab (Humira).
Note: For research use only. Not suitable for clinical or therapeutic use.